Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INTS 
Intensity Therapeutics, Inc. Common stock (INTS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: INTS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.92
1 Year Target Price $2.92
| 1 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.26% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.89M USD | Price to earnings Ratio - | 1Y Target Price 2.92 |
Price to earnings Ratio - | 1Y Target Price 2.92 | ||
Volume (30-day avg) 5 | Beta 3.67 | 52 Weeks Range 0.19 - 3.44 | Updated Date 10/16/2025 |
52 Weeks Range 0.19 - 3.44 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -122.68% | Return on Equity (TTM) -334.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11153974 | Price to Sales(TTM) - |
Enterprise Value 11153974 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.72 | Shares Outstanding 49055462 | Shares Floating 41076219 |
Shares Outstanding 49055462 | Shares Floating 41076219 | ||
Percent Insiders 12.71 | Percent Institutions 6.59 |
Upturn AI SWOT
Intensity Therapeutics, Inc. Common stock
Company Overview
History and Background
Intensity Therapeutics, Inc. (INTY) is a clinical-stage biotechnology company focused on developing novel, locally delivered cancer immunotherapies. Founded to improve patient outcomes by directly targeting tumors with their proprietary DfuseRxu2120 technology.
Core Business Areas
- Oncolytic Immunotherapy Development: Development of DfuseRxu2120-based therapies to induce tumor cell death and stimulate systemic anti-cancer immune responses. Lead product candidate is INT230-6.
Leadership and Structure
Lewis H. Bender is the CEO and President. The company is structured around research, development, and clinical trial operations, with a focus on oncology.
Top Products and Market Share
Key Offerings
- INT230-6: INT230-6 is Intensity Therapeutics' lead product candidate, a novel formulation designed for direct intratumoral injection to promote tumor regression and systemic anti-tumor immunity. It is currently in Phase 1/2 clinical trials. Market share data is not yet available as the product is not yet commercialized. Competitors in cancer immunotherapy include large pharmaceutical companies such as Merck (MRK), Bristol Myers Squibb (BMY), and Roche (ROG).
Market Dynamics
Industry Overview
The oncology therapeutics market is large and rapidly growing, driven by increasing cancer incidence and advancements in immunotherapy and targeted therapies.
Positioning
Intensity Therapeutics is positioned as an innovative player in the immuno-oncology space, focusing on a novel drug delivery method to enhance treatment efficacy and reduce systemic toxicity. The strategy of directly injecting the therapeutic agents into the tumor sets it apart from traditional systemic treatments.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Intensity Therapeutics targets specific tumor types and treatment niches within this larger market. The total addressable market depends on the success of INT230-6 in clinical trials and subsequent regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel DfuseRxu2120 technology platform
- Potential for improved efficacy and reduced toxicity compared to systemic therapies
- Focus on intratumoral drug delivery
- Early-stage clinical data showing promising results
Weaknesses
- Limited financial resources as a small-cap biotech company
- Reliance on successful clinical trial outcomes
- Competition from larger, more established pharmaceutical companies
- Product not yet approved for commercial use
Opportunities
- Expansion into additional cancer types
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results driving investor interest
- Potential for breakthrough therapy designation
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other emerging cancer therapies
- Market adoption challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- AZN
Competitive Landscape
Intensity Therapeutics' competitive advantage lies in its unique intratumoral delivery system. However, it faces significant competition from larger, more established pharmaceutical companies with broader pipelines and greater resources.
Growth Trajectory and Initiatives
Historical Growth: Intensity Therapeutics' growth is tied to the advancement of its pipeline. Historical growth would be primarily based on pre-clinical and clinical data. Stock prices would be related to funding, partnerships, and results.
Future Projections: Future growth projections are dependent on clinical trial outcomes and regulatory approvals for INT230-6 and other pipeline candidates. Analyst estimates would be available from various financial data providers.
Recent Initiatives: Recent initiatives include advancing INT230-6 through clinical trials and exploring new applications of the DfuseRxu2120 technology.
Summary
Intensity Therapeutics is a clinical-stage biotechnology company with a promising novel drug delivery technology. The company's future depends on the success of its lead candidate, INT230-6, in clinical trials. Potential threats include clinical trial failures, regulatory hurdles, and competition from larger companies. The company should look out for opportunities for partnerships and collaborations to expand its resources and reach.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- ClinicalTrials.gov
- Financial News Sources
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in biotechnology companies carries significant risk. Market share are approximate and subject to change. Current clinical trial and market data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intensity Therapeutics, Inc. Common stock
Exchange NASDAQ | Headquaters Shelton, CT, United States | ||
IPO Launch date 2023-06-30 | Founder, President, CEO & Chairman of the Board Mr. Lewis H. Bender M.A., M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | |
Full time employees 5 | |||
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.